Alliance Growers has organized into four divisions
in order to focus our potential for success in the medical marijuana market.
Click on a pillar for more info:
- The first Cannabis Biotech Complex will be a 58,000 square foot facility built in Mission, BC
Cannabis Biotech Complex
- Building strategic partnerships with licensed cannabis producers at various stages in the licensing process.
Licensed Cannabis Growers
- Medical grade CBD has become highly sought after compound in the treatment of a range of medical issues.
CBD Oil Supply & Distribution
- Developing technologies that will improve the quantity, the consistency and distribution of cannabis production.
Research & Technology
With its partner WFS Pharmagreen, Alliance Growers Corp is establishing the first in a series of Cannabis Biotech Complexes in Mission, BC.
The purpose of these facilities is to supply licenced cannabis growers with high quality ready-to-grow starter crops in the form of planet clones. These planetlets are produced using our own proprietary in-vitro “Chibafreen Process.”
The Mission Complex will be a 58,000 square foot, semi-automated, fully finished, facility. A state-of-the-art greenhouse will be part of the layout, allowing the facility to operate as a year-round nursery for the newly cultured cannabis crop. The facility will also house a cold storage area utilizing a proprietary Cryotissue Cold Storage technology for long-term preservation of plant tissue samples.
WFS Pharmagreen has already purchased the land upon which the proposed Cannabis Biotech Complex will be established. The new facility will be built and operated through WFS Pharmagreen’s new subsidiary, BC New Co.
Alliance Growers has entered into a binding Letter of Intent with WFS Pharmagreen Inc. to acquire an equity stake in this subsidiary. Alliance Growers will purchase a non-dilutive 30% equity interest in BC New Co., bringing their project revenue share to 30%. Alliance Growers will purchase up to 30% of BC New Co. shares for total consideration of $4.5 million within the next nine months. Alliance Growers will elect one of the three Directors of BC New Co.
The projected cost of the building is $15 million (CDN), and the projected annual plantlet production is 10 million. The plantlets are anticipated to sell for a price of $5 per unit for $50 million in gross revenues, while the cost per plantlet is anticipated at $1 (CDN). The projected annual profit $40 million (CDN).
Alliance Growers has already acquired interests in two ACMPR applicants, most notably 100% of BiocannaTech, a late-stage ACMPR applicant based in Québec, and Canwe, a private company based in Ontario, that has applied for its ACMPR license and is currently in the review and security clearance stage.
Building partnerships with growers will allow Alliance Growers to secure long-term plantlet sale contracts for the Cannabis Biotech Complex and off-take agreements for wholesale cost cannabis flowers for CBD oil extraction.
Alliance Growers has entered into an exclusive agreement to fully acquire Biocannatech Inc., located in Côte Saint-Luc Québec. Biocannatech is in the final expedited phase of Health Canada’s “Access to Cannabis for Medical Purposes Regulations” (ACMPR) approval for the production and sales of Medical Marijuana.
Biocannatech has an application to build a 10,000 square feet facility with an attached 120,000 square feet warehouse for a projected gross revenue of $10 million per year. Construction is targeted for March 2018. With additional approval, the facility can be expanded to 70,000 square feet with a projected gross revenue of $70 million per year. The expansion is estimated to be operational in late 2019.
Alliance Growers will supply financing and resources to build out the medical marijuana facility in preparation for the inspection required to obtain a growing license. Once Health Canada is satisfied with a successful crop, Alliance Growers will be granted its distribution license.
Québec is considered the optimal locale for an ACMPR producer. The province is host to 20% of Canada’s population, yet it has only had two ACMPR licenses approved to date with only one currently producing. In this respect, Québec is currently vastly underrepresented relative to other provinces in Canada. The Québec government has always maintained an aggressive approach to obtaining 25% of any industry in which the rest of Canada intends to do business. Specifically regarding ACMPR licenses, Québec has publicly stated that they want Health Canada to process all 16 of the license applications in the province and have them approved expeditiously. When it comes time for Québec licensees to purchase their supply, they will have a high priority on purchasing from Québec growers.
Canwe Growers Inc.
Alliance Growers has acquired terms on a 5% interest in New Maple Holdings, the parent company of its wholly owned subsidiary Canwe Growers Inc., which is a private Ontario-based company that has applied for a producer’s license under ACMPR.
Canwe has access to a 22 acre property 1.5 hours north-west of Toronto, where it plans to build a facility focused on producing clean, premium quality cannabis. The company has amassed a highly qualified team which includes licensed producer MedReleaf Corp.’s former Head Grower Jack Yu, an expert cannabis grower well-versed in the cultivation of cannabis from seed to sale.
In January 2018, Canwe received confirmation from Health Canada that it has completed the security clearance stage and has entered the final review stage of the application process. The company has retained an experienced project management firm to oversee the design and build of its planned state-of-the-art production facility and is projected to be licensed and operational by early 2019.
Jamaican Cannabis Company Investment
Alliance Growers is in discussions with a private licensed Jamaican cannabis company regarding a significant strategic investment. Alliance Growers has commenced due diligence for the investment of this company which is planning for an IPO later this year.
The private Jamaican company has established operations and production facilities with a Tier 1 Cultivator’s license and a Tier 3 Processing license, allowing them to cultivate and process cannabis for medical, scientific, and therapeutic purposes, including the manufacturing of cannabis-based products. The company’s mission is to produce quality medicinal products in Jamaica that carry the unique qualities demanded in Jamaica’s holistic healing culture. The Jamaican company will be exporting cannabinoids and terpenoids through joint ventures with selective Canadian and European Licensed Distributors, and develop a new world class cannabis flowers, extracts, and infused products.
Alliance Growers will continue seeking further strategic investment opportunities in additional ACMPR companies to secure plantlet sales and CBD offtake agreements.
With its own world-class cannabidiol oil (CBD oil) extraction and processing facility as part of the Cannabis Biotech Complex, Alliance Growers aims to become a world leader in the production and supply of pharmaceutical grade CBD oil.
Alliance Growers is working on an agreement for a 20% equity investment in an Israeli medical cannabis company developing pharmaceutical grade CBD oil processing and technologies.
The Israeli government has encouraged cannabis research since the 1960’s, and in 2017 the government announced it’s investment of $2.13 million in new research projects. Israel’s Health Ministry’s Medical Cannabis Unit believes cannabis should be considered in the same manner as any other medicinal product. Licensed suppliers provide cannabis to Israel’s roughly 26,000 registered patients, creating a domestic market of about $15 million to $20 million.
Hebrew University researchers have synthesized 22 versions of the cannabinoid molecule that show great potential for treating neurological and inflammatory diseases. After some success in using substance to treat epileptics, researchers will launch clinical trials to check the effect of cannabis oils on individuals with severe development disorders such as autism.
International companies regularly join forces with Israeli academic and medical institutions to create new medications. In February of 2017, an Israeli government committee approved a plan that would allow medical marijuana companies to export products internationally.
The Hemp Business Journal reports that the CBD market is growing at a rate of 30% per annum, and forecasts that sales of CBD Oils from marijuana-based sources are expected to reach $1,650,000,000, or 79% of the Total CBD Market of $2,100,000,000 by 2020. Generated revenue from the extraction, processing, and resale of cannabidiol (CBD) oil in Canada, USA, and offshore producers is estimated at several million dollars per year.
The medical marijuana market is changing and expanding faster than ever. In light of this new market opportunity, Alliance Growers is committed to being at the cutting edge of competitive innovation while setting the standards that define the industry.
Botanical Research In Motion International Inc. (B.R.I.M.)
Under the guidance of Peter Wojcik and Dr. Fawzia Afreen, B.R.I.M and Alliance Growers will pursue and develop new methods and technologies to establish a presence in the industry’s newest fields.
Alliance Growers has secured use of B.R.I.M.’s proprietary, state-of-art Chibafreen in-vitro plant production technology which produces ready-to-grow platelets from existing plant strains.
The Chibafreen process utilizes clean tissue culture to clone new growth while limiting genetic drift. This allows growers to ensure a consistent quality and yield in each growing season. The process is efficient enough to produce over one million plantlets per year and can be adapted to all varieties of flora to potentially serve additional agricultural industries.
B.R.I.M. has also developed a proprietary Cryotissue Cold Storage technology for long-term preservation of plant tissue samples. This feature will provide cultivators with the ability to preserve desired plant breeds and have specific strains produced as needed.
CBD DANA Hemp Strain
Alliance Grower has secured access to a proprietary CBD strain which will become Alliance Growers’ flagship for CBD hemp farming.
Named “CBD DANA,” the stain is unique in its CBD to THC content ratio. The strain has been tested for a content of at least 10% CBD with more than 0.3% THC. This CBD yield is substantially greater than traditional hemp strains which typically have at most a 1% content. The lower THC content allows the strain to be classified as “industrial hemp” which makes it ideal for cultivation with less restrictive regulation.
The female plantlets produced in the Tissue Culture Lab at the Cannabis Biotech Complex will be available for hemp farmers on a global scale. Providing hemp farmers with all female, fully rooted plantlets of the strain will provide a significant yield in CBD production for hemp farmers.
As the Cannabinoids are primarily produced in the flower portion of the female plant, eliminating male plants from the crop can allow an additional 80% increased yield in the unpollinated flowers. Selecting for only female plantlets is the best way to ensure this compared to traditional planting from seeds.
The commercial production of hemp starts with planting 200,000 female-only tissue cultured plantlets of the proprietary CBD Dana strain in 5 acres of glass greenhouses. Stage two involves moving the plants to a contracted hemp farmer with a secure, 20 acre open field. The plants will yield approximately 100,000 kilograms of CBD flower which in turn will yield 3,000 kilograms of 99% pure CBD Crystals. At approximately $20,000 per kilo this yields a $60 million gross revenue with costs ranging from $20 million to $30 million depending on the lease and contract farming arrangement and the cost of extraction.